Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Lymphoid 1

Conditions

Neurotoxicity Syndromes 1Mucositis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hematologic Neoplasms 1

Interventions

Rituximab 47Cyclophosphamide 45fludarabine 22Filgrastim 21Lenalidomide 18fludarabine phosphate 17Prednisone 16Radiotherapy 15Peripheral Blood Stem Cell Transplantation 15Etoposide 15Vincristine 14Doxorubicin 14Melphalan 13Busulfan 13pembrolizumab 11Tacrolimus 11Methotrexate 10Gemcitabine 10ibrutinib 9Bendamustine Hydrochloride 9Alemtuzumab 9obinutuzumab 8Bortezomib 8Vorinostat 7Mycophenolic Acid 7Granulocyte Colony-Stimulating Factor 7Carboplatin 7Azacitidine 7venetoclax 6Whole-Body Irradiation 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma × glucarpidase × Clear all
NCT00727831 2014-01-27

Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

University College, London

Phase 1/2 Completed
4 enrolled
LymphoidOther

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Neurotoxicity Syndromes, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡